Tissue and serum proteomic profiling for diagnostic and prognostic bladder cancer biomarkers

Expert Review of Proteomics

Volumn 7, Issue 6, 2010, Pages 897-906

  Schwamborn, Kristina ^a   Gaisa, Nadine T ^a   Henkel, Corinna ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

2D gel electrophoresis; bladder cancer; MALDI; mass spectrometry; matrix assisted laser desorption ionization; pattern profiling; proteomics; serum

Indexed keywords

BIOLOGICAL MARKER; CALGRANULIN A; CYSTATIN B; DNA; FATTY ACID BINDING PROTEIN 4; LIPOCORTIN 1; LIPOCORTIN 5; PEPTIDE; POLYPEPTIDE; PROTEIN; RNA;

BLADDER CANCER; CANCER DIAGNOSIS; CAPILLARY ELECTROPHORESIS; CYSTOSCOPY; DIAGNOSTIC TEST ACCURACY STUDY; EARLY DIAGNOSIS; HUMAN; LABORATORY DIAGNOSIS; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEOMICS; REVIEW; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TISSUE CULTURE; TUMOR ASSOCIATED LEUKOCYTE; TWO DIMENSIONAL GEL ELECTROPHORESIS; URINALYSIS; WESTERN BLOTTING;

ANIMALS; HUMANS; MASS SPECTROMETRY; PROGNOSIS; PROTEIN ARRAY ANALYSIS; PROTEOME; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL; TWO-DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; URINARY BLADDER NEOPLASMS;

EID: 78650483623     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/epr.10.82     Document Type: Review

References (86)

1. Parkin DM. The global burden of urinary bladder cancer. Scand. J. Urol. Nephrol. Suppl. (218), 12-20 (2008).
2. Messing EM, Madeb R, Feng C et al. Grade and stage at presentation do not predict mortality in patients with bladder cancer who survive their disease. J. Clin. Oncol. 27(15), 2443-2449 (2009).
3. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 374(9685), 239-249 (2009).
4. Hong YM, Loughlin KR. Economic impact of tumor markers in bladder cancer surveillance. Urology 71(1), 131-135 (2008).
5. Talwar R, Sinha T, Karan SC et al. Voided urinary cytology in bladder cancer: is it time to review the indications? Urology 70(2), 267-271 (2007). (Pubitemid 47362257)
6. Knuchel R, Lindemann-Docter K. [Urine-based tumour diagnostics for bladder cancer: effects of the new histopathological classification - food for thought]. Urologe A 48(6), 598-608 (2009).
7. Zaak D, Karl A, Knuchel R et al. Diagnosis of urothelial carcinoma of the bladder using fluorescence endoscopy. BJU Int. 96(2), 217-222 (2005). (Pubitemid 41097708)
8. Goodison S, Rosser CJ, Urquidi V. Urinary proteomic profiling for diagnostic bladder cancer biomarkers. Expert Rev. Proteomics 6(5), 507-514 (2009).
9. Liotta LA, Petricoin EF. Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. J. Clin. Invest. 116(1), 26-30 (2006).
10. Ecke TH, Schlechte HH, Schulze G, Lenk SV, Loening SA. Four tumour markers for urinary bladder cancer - tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation. Anticancer Res. 25(1B), 635-641 (2005). (Pubitemid 40470075)
11. von Knobloch R, Brandt H, Hofmann R. Molecular serological diagnosis in transitional cell bladder cancer. Ann. NY Acad. Sci. 1022, 70-75 (2004). (Pubitemid 38951584)
12. Valenzuela MT, Galisteo R, Zuluaga A et al. Assessing the use of p16(INK4a) promoter gene methylation in serum for detection of bladder cancer. Eur. Urol. 42(6), 622-628 (2002). (Pubitemid 35462344)
13. Varambally S, Cao Q, Mani RS et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322(5908), 1695-1699 (2008).
14. Catto JW, Miah S, Owen HC et al. Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res. 69(21), 8472-8481 (2009).
15. Celis JE, Ostergaard M, Basse B et al. Loss of adipocyte-type fatty acid binding protein and other protein biomarkers is associated with progression of human bladder transitional cell carcinomas. Cancer Res. 56(20), 4782-4790 (1996). (Pubitemid 26338085)
16. Orenes-Piero E, Barderas R, Rico D et al. Serum and tissue profiling in bladder cancer combining protein and tissue arrays. J. Proteome Res. 9(1), 164-173 (2010).
17. Villanueva J, Shaffer DR, Philip J et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J. Clin. Invest. 116(1), 271-284 (2006). (Pubitemid 43121812)
18. Schwamborn K, Krieg RC, Grosse J et al. Serum proteomic profiling in patients with bladder cancer. Eur. Urol. 56(6), 989-996 (2009).
19. Vrooman OP, Witjes JA. Urinary markers in bladder cancer. Eur. Urol. 53(5), 909-916 (2008).
20. Celis A, Rasmussen HH, Celis P et al. Short-term culturing of low-grade superficial bladder transitional cell carcinomas leads to changes in the expression levels of several proteins involved in key cellular activities. Electrophoresis 20(2), 355-361 (1999). (Pubitemid 29125023)
21. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 1(11), 845-867 (2002).
22. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 411(6835), 375-379 (2001).
23. Norden AG, Rodriguez-Cutillas P, Unwin RJ. Clinical urinary peptidomics: learning to walk before we can run. Clin. Chem. 53(3), 375-376 (2007). (Pubitemid 46447931)
24. Schaub S, Wilkins J, Weiler T, Sangster K, Rush D, Nickerson P. Urine protein profiling with surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry. Kidney Int. 65(1), 323-332 (2004). (Pubitemid 38037520)
25. Duan X, Yarmush D, Berthiaume F, Jayaraman A, Yarmush ML. Immunodepletion of albumin for two-dimensional gel detection of new mouse acute-phase protein and other plasma proteins. Proteomics 5(15), 3991-4000 (2005). (Pubitemid 41502494)
26. Petricoin EF, Ardekani AM, Hitt BA et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359(9306), 572-577 (2002). (Pubitemid 34178440)
27. Baggerly KA, Morris JS, Edmonson SR, Coombes KR. Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J. Natl Cancer Inst. 97(4), 307-309 (2005).
28. Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J. Natl Cancer Inst. 96(5), 353-356 (2004).
29. Anderson NL. The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin. Chem. 56(2), 177-185 (2010).
30. Diamandis EP. Serum proteomic profiling by matrix-assisted laser desorption-ionization time-of-flight mass spectrometry for cancer diagnosis: next steps. Cancer Res. 66(11), 5540-5541 (2006). (Pubitemid 43927101)
31. Tuck MK, Chan DW, Chia D et al. Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J. Proteome Res. 8(1), 113-117 (2009).
32. van der Merwe DE, Oikonomopoulou K, Marshall J, Diamandis EP. Mass spectrometry: uncovering the cancer proteome for diagnostics. Adv. Cancer Res. 96, 23-50 (2007).
33. Gromov P, Moreira JM, Gromova I, Celis JE. Proteomic strategies in bladder cancer: from tissue to fluid and back. Proteomics Clin. Appl. 2(7-8), 974-988 (2008).
34. Celis JE, Gromov P. Proteomics in translational cancer research: toward an integrated approach. Cancer Cell 3(1), 9-15 (2003). (Pubitemid 37448548)
35. Anderson NL. The roles of multiple proteomic platforms in a pipeline for new diagnostics. Mol. Cell. Proteomics 4(10), 1441-1444 (2005).
36. Miura D, Fujimura Y, Tachibana H, Wariishi H. Highly sensitive matrix-assisted laser desorption ionization-mass spectrometry for high-throughput metabolic profiling. Anal. Chem. 82(2), 498-504 (2010).
37. Apweiler R, Aslanidis C, Deufel T et al. Approaching clinical proteomics: current state and future fields of application in fluid proteomics. Clin. Chem. Lab. Med. 47(6), 724-744 (2009).
38. Yates JR, Ruse CI, Nakorchevsky A. Proteomics by mass spectrometry: approaches, advances, and applications. Annu. Rev. Biomed. Eng. 11, 49-79 (2009).
39. Soldi M, Sarto C, Valsecchi C et al. Proteome profile of human urine with two-dimensional liquid phase fractionation. Proteomics 5(10), 2641-2647 (2005). (Pubitemid 40966491)
40. Makawita S, Diamandis EP. The bottleneck in the cancer biomarker pipeline and protein quantification through mass spectrometry-based approaches: current strategies for candidate verification. Clin. Chem. 56(2), 212-222 (2010).
41. Vorderwulbecke S, Cleverley S, Weinberger SR, Wiesner A. Protein quantification by the SELDI-TOF-MS-based ProteinChip[reg] system. Nat. Methods 2(5), 393-395 (2005).
42. Tolson JP, Flad T, Gnau V et al. Differential detection of S100A8 in transitional cell carcinoma of the bladder by pair wise tissue proteomic and immunohistochemical analysis. Proteomics 6(2), 697-708 (2006). (Pubitemid 43208048)
43. Schultz IJ, De Kok JB, Witjes JA et al. Simultaneous proteomic and genomic analysis of primary Ta urothelial cell carcinomas for the prediction of tumor recurrence. Anticancer Res. 27(2), 1051-1058 (2007). (Pubitemid 46587022)
44. Fiedler GM, Baumann S, Leichtle A et al. Standardized peptidome profiling of human urine by magnetic bead separationand matrix-assisted laser desorption/ ionization time-of-flight mass spectrometry. Clin. Chem. 53(3), 421-428 (2007). (Pubitemid 46447938)
45. Engwegen JY, Gast MC, Schellens JH, Beijnen JH. Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. Trends Pharmacol. Sci. 27(5), 251-259 (2006).
46. Diamandis EP. Oncopeptidomics: a useful approach for cancer diagnosis? Clin. Chem. 53(6), 1004-1006 (2007).
47. Aebersold R, Goodlett DR. Mass spectrometry in proteomics. Chem Rev. 101(2), 269-295 (2001). (Pubitemid 32325797)
48. Niu HT, Zhang YB, Jiang HP et al. Differences in shotgun protein expression profile between superficial bladder transitional cell carcinoma and normal urothelium. Urol. Oncol. 27(4), 400-406 (2009).
49. Wang S, Zhao X, Mao Y, Cheng Y. Novel approach for developing urinary nucleosides profile by capillary electrophoresis-mass spectrometry. J. Chromatogr. A 1147(2), 254-260 (2007). (Pubitemid 46466835)
50. Hamacher M, Stephan C, Meyer HE, Eisenacher M. Data handling and processing in proteomics. Expert Rev. Proteomics 6(3), 217-219 (2009).
51. Theodorescu D, Wittke S, Ross MM et al. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol. 7(3), 230-240 (2006). (Pubitemid 43286453)
52. Schiffer E, Vlahou A, Petrolekas A et al. Prediction of muscle-invasive bladder cancer using urinary proteomics. Clin. Cancer Res. 15(15), 4935-4943 (2009).
53. Fang X, Balgley BM, Lee CS. Recent advances in capillary electrophoresis-based proteomic techniques for biomarker discovery. Electrophoresis 30(23), 3998-4007 (2009).
54. Klose J, Kobalz U. Two-dimensional electrophoresis of proteins: an updated protocol and implications for a functional analysis of the genome. Electrophoresis 16(6), 1034-1059 (1995).
55. Hoving S, Voshol H, van Oostrum J. Towards high performance two-dimensional gel electrophoresis using ultrazoom gels. Electrophoresis 21(13), 2617-2621 (2000). (Pubitemid 30646296)
56. Gorg A, Postel W, Gunther S et al. Approach to stationary two-dimensional pattern: influence of focusing time and immobiline/carrier ampholytes concentrations. Electrophoresis 9(1), 37-46 (1988).
57. Unlu M, Morgan ME, Minden JS. Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 18(11), 2071-2077 (1997). (Pubitemid 27501267)
58. Sitek B, Luttges J, Marcus K et al. Application of fluorescence difference gel electrophoresis saturation labelling for the analysis of microdissected precursor lesions of pancreatic ductal adenocarcinoma. Proteomics 5(10), 2665-2679 (2005). (Pubitemid 40966494)
59. Rabilloud T. Membrane proteins and proteomics: love is possible, but so difficult. Electrophoresis 30(Suppl. 1), S174-S180 (2009).
60. Miller MJ, Parmelee DC, Benjamin T, Sechi S, Dooley KL, Kadlubar FF. Plasma proteins as early biomarkers of exposure to carcinogenic aromatic amines. Chem. Biol. Interact. 93(3), 221-234 (1994). (Pubitemid 24290241)
61. Ornstein DK, Gillespie JW, Paweletz CP et al. Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis 21(11), 2235-2242 (2000).
62. Sheng KH, Yao YC, Chuang SS, Wu H, Wu TF. Search for the tumor-related proteins of transition cell carcinoma in Taiwan by proteomic analysis. Proteomics 6(3), 1058-1065 (2006). (Pubitemid 43260230)
63. Moreira JM, Ohlsson G, Gromov P et al. Bladder cancer-associated protein, a potential prognostic biomarker in human bladder cancer. Mol. Cell. Proteomics 9(1), 161-177 (2010).
64. Ohlsson G, Moreira JM, Gromov P, Sauter G, Celis JE. Loss of expression of the adipocyte-type fatty acid-binding protein (A-FABP) is associated with progression of human urothelial carcinomas. Mol. Cell. Proteomics 4(4), 570-581 (2005). (Pubitemid 40590573)
65. Boiteux G, Lascombe I, Roche E et al. A-FABP, a candidate progression marker of human transitional cell carcinoma of the bladder, is differentially regulated by PPAR in urothelial cancer cells. Int. J. Cancer 124(8), 1820-1828 (2009).
66. Celis JE, Rasmussen HH, Vorum H et al. Bladder squamous cell carcinomas express psoriasin and externalize it to the urine. J. Urol. 155(6), 2105-2112 (1996). (Pubitemid 26146716)
67. Celis JE, Celis P, Palsdottir H et al. Proteomic strategies to reveal tumor heterogeneity among urothelial papillomas. Mol. Cell. Proteomics 1(4), 269-279 (2002).
68. Langbein S, Lehmann J, Harder A et al. Protein profiling of bladder cancer using the 2D-PAGE and SELDI-TOF-MS technique. Technol. Cancer Res. Treat. 5(1), 67-72 (2006). (Pubitemid 43278320)
69. Feldman AS, Banyard J, Wu CL, McDougal WS, Zetter BR. Cystatin B as a tissue and urinary biomarker of bladder cancer recurrence and disease progression. Clin. Cancer Res. 15(3), 1024-1031 (2009).
70. Getzenberg RH, Konety BR, Oeler TA et al. Bladder cancer-associated nuclear matrix proteins. Cancer Res. 56(7), 1690-1694 (1996). (Pubitemid 26104035)
71. Van Le TS, Myers J, Konety BR, Barder T, Getzenberg RH. Functional characterization of the bladder cancer marker, BLCA-4. Clin. Cancer Res. 10(4), 1384-1391 (2004). (Pubitemid 38365233)
72. Barboro P, Rubagotti A, Orecchia P et al. Differential proteomic analysis of nuclear matrix in muscle-invasive bladder cancer: potential to improve diagnosis and prognosis. Cell Oncol. 30(1), 13-26 (2008). (Pubitemid 351161036)
73. Haab BB, Dunham MJ, Brown PO. Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions. Genome Biol. 2(2), RESEARCH0004 (2001).
74. Sanchez-Carbayo M, Socci ND, Lozano JJ, Haab BB, Cordon-Cardo C. Profiling bladder cancer using targeted antibody arrays. Am. J. Pathol. 168(1), 93-103 (2006). (Pubitemid 43062562)
75. Kozarova A, Petrinac S, Ali A, Hudson JW. Array of informatics: applications in modern research. J. Proteome Res. 5(5), 1051-1059 (2006). (Pubitemid 43727782)
76. Hanash S. Disease proteomics. Nature 422(6928), 226-232 (2003). (Pubitemid 36362760)
77. Banks RE, Dunn MJ, Hochstrasser DF et al. Proteomics: new perspectives, new biomedical opportunities. Lancet 356(9243), 1749-1756 (2000).
78. Pastwa E, Somiari SB, Czyz M, Somiari RI. Proteomics in human cancer research. Proteomics Clin. Appl. 1(1), 4-17 (2007).
79. Anderson L, Seilhamer J. A comparison of selected mRNA and protein abundances in human liver. Electrophoresis 18(3-4), 533-537 (1997). (Pubitemid 27174443)
80. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer 5(11), 845-856 (2005). (Pubitemid 41746029)
81. Shariat SF, Chade DC, Karakiewicz PI et al. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J. Urol. 183(1), 68-75 (2010).
82. Shariat SF, Karakiewicz PI, Godoy G et al. Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study. Clin. Cancer Res. 15(22), 7012-7019 (2009).
83. Friedman DB, Lilley KS. Optimizing the difference gel electrophoresis (DIGE) technology. Methods Mol. Biol. 428, 93-124 (2008).
84. Sitek B, Sipos B, Kloppel G et al. Application of fluorescence dye saturation labeling for differential proteome analysis of 1,000 microdissected cells from pancreatic ductal adenocarcinoma precursor lesions. Methods Mol. Biol. 425, 1-14 (2008).
85. Horner MJ, Ries LAG, Krapcho M et al. Seer Cancer Statistics Review, 1975-2006. National Cancer Institute, MD, USA (2009) http://seer.cancer.gov/csr/ 1975-2006/
86. Oosterlinck W, Van Der Meijden A, Sylvester R et al. Guidelines on TaT1 (non-muscle invasive) bladder cancer (2006) www.uroweb.org/fileadmin/tx- eauguidelines/2006/Full/05%20TaT1%20 Bladder%20Cancer.pdf